Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts

Cancer Research

Volumn 74, Issue 21, 2014, Pages 5978-5988

  Ambrogio, Chiara ^a   Carmona, Francisco J ^b   Vidal, August ^c   Falcone, Mattia ^d   Nieto, Patricia ^a   Romero, Octavio A ^b   Puertas, Sara ^b   Vizoso, Miguel ^b   Nadal, Ernest ^b   Poggio, Teresa ^d   Sánchez Céspedes, Montserrat ^b   Esteller, Manel ^b,e,f   Mulero, Francisca ^a   Voena, Claudia ^d   Chiarle, Roberto ^d,g   Barbacid, Mariano ^a   Santamaría, David ^a   Villanueva, Alberto ^b,h  

^a Structural Biology and Biocomputing Programme   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h Xenopat SL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CISPLATIN; CRIZOTINIB; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; PROTEIN KINASE LKB1; PROTEIN LGR6; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER MODEL; CANCER TRANSPLANTATION; CARCINOGENESIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CRYOPRESERVATION; EMBRYO; GENE MUTATION; IN VIVO STUDY; LKB1 GENE; LUNG CANCER CELL LINE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; ORTHOTOPIC TRANSPLANTATION; PRIMARY TUMOR; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR GROWTH; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; DRUG EFFECTS; EVOLUTION; GENETICS; HUMAN; LUNG NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TUMOR CELL LINE;

ALLOGRAFTS; ANIMALS; BIOLOGICAL EVOLUTION; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASMS, EXPERIMENTAL;

EID: 84909592556     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1606     Document Type: Article

References (26)

1. World Health Organization (WHO). World Cancer Report 2008 [Internet]. Lyon, France: IARC Press; 2008. p. 512. Available from: http:// www.who.int/cancer/publications/world-cancer-report2008/en/.
2. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst 2010;102:1310-21.
3. Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res [Internet] 2003;9:5532-9. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/14654533.
4. Kwon M, Berns A. Mouse models for lung cancer. Mol Oncol [Internet] 2013;7:165-77. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/23481268.
5. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010;18:63-73.
6. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003;4:111-20.
7. Li J, Zhang Z, Dai Z, Plass C, Morrison C, Wang Y, et al. LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene 2003;22:1243-6.
8. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/ American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
9. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005;65:10280-8.
10. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
11. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007;26:7825-32.
12. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 50 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
13. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG. An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res [Internet] 2009;15:6386-90. Available from: http://www.ncbi.nlm.nih. gov/pubmed/19808871.
14. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990;5:1603-10.
15. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
16. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609-22.
17. Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M, et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 2010;5:e11712.
18. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med [Internet] 2002;346:92-8. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=11784875\nfile://cdhb.local/dfsgeneral/CHC12homelink/DavidG3/Documents/Epapers/Schiller.
19. Yamane Y, Ishii G,GotoK, Kojima M, Nakao M, Shimada Y, et al. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. J Thorac Oncol 2010;5:49-55.
20. Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, et al. Coclinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res 2014;20:1204-11.
21. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010;22:215-22.
22. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
23. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 2010;107:18545-50.
24. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DMF. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 2009;326:1707-11.
25. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010;24:837-52.
26. Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011;20:289-99.